Preprint Review Version 2 Preserved in Portico This version is not peer-reviewed

Gypsogenin Fighting for A Position in The Pentacyclic Triter-penes Game of Thrones on Anti-Cancer Therapy: A Critical Review

Version 1 : Received: 22 June 2023 / Approved: 23 June 2023 / Online: 23 June 2023 (11:55:35 CEST)
Version 2 : Received: 5 July 2023 / Approved: 10 July 2023 / Online: 10 July 2023 (14:23:12 CEST)

How to cite: Radwan, M.; Abd-Alla, H.I.; Elmezayen, H.; Abourehab, M.A.; El‐Beeh, M.E.; Tateishi, H.; Otsuka, M.; Fujita, M. Gypsogenin Fighting for A Position in The Pentacyclic Triter-penes Game of Thrones on Anti-Cancer Therapy: A Critical Review. Preprints 2023, 2023061671. https://doi.org/10.20944/preprints202306.1671.v2 Radwan, M.; Abd-Alla, H.I.; Elmezayen, H.; Abourehab, M.A.; El‐Beeh, M.E.; Tateishi, H.; Otsuka, M.; Fujita, M. Gypsogenin Fighting for A Position in The Pentacyclic Triter-penes Game of Thrones on Anti-Cancer Therapy: A Critical Review. Preprints 2023, 2023061671. https://doi.org/10.20944/preprints202306.1671.v2

Abstract

Abstract: In the last decade, gypsogenin has widely grabbed the attention of medicinal chemists by virtue of its prominent anti-cancer potential. Despite its late identification, gypsogenin proved itself as a new an-ti-proliferative player battling for a front position among other classic pentacyclic triterpenes such as oleanolic acid, glycyrrhetinic acid, ursolic acid, betulinic acid, and celastrol. Herein, we present insights into the anti-cancer activity of gypsogenin and its semisynthetic derivatives and go further by introducing our perspective to judiciously guide the prospect rational design. The present article opens a new venue for better exploitation of gypsogenin chemical entity as a lead compound in cancer chemotherapy. To the best of our knowledge, this is the first review article exploring the anti-cancer activity of gypsogenin derivatives.

Keywords

pentacyclic triterpenes; gypsogenin; anti-cancer

Subject

Chemistry and Materials Science, Medicinal Chemistry

Comments (1)

Comment 1
Received: 10 July 2023
Commenter: Mohamed Radwan
Commenter's Conflict of Interests: Author
Comment: Addition of a full synthetic part
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.